# Phosphatidylcholine Supplementation in Infants

> **NCT01905605** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Colorado, Denver**

## Conditions studied

- Schizophrenia
- Diminished P50 Sensory Gating

## Interventions

- **DRUG:** phosphatidylcholine supplementation
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01905605
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-09
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding not secured. IRB approval has been withdrawn as of January 2017.
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01905605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01905605, "Phosphatidylcholine Supplementation in Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01905605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*